Aleafia Health

Aleafia Health rates Neutral with a composite score just above 41 and low conviction at 2/5. The regulatory pillar leads at 58, supported by Canada’s favorable jurisdiction posture and a clean enforcement record, while weak filing cadence constrains the contribution. The market pillar contributes 40 because no institutional pricing quote is available. Fundamentals score 35 as rapid sales expansion is overwhelmed by severe margin pressure, continued losses, limited scale, and a stretched financial condition. Editorial ranks last at 30, reflecting no identified newsroom or briefing activity in CIN newsroom coverage.

Licensed fundamentals data show year-over-year revenue growth of roughly 86%, earning the maximum revenue-growth subscore. That momentum has not translated into viable economics: gross margin is approximately negative 22%, while operating margin is near negative 81%. Net income remains a loss of about $34.6 million, and EBITDA is negative by roughly $11.8 million, confirming that operating performance remains structurally weak rather than merely burdened by below-the-line items. A market capitalization near $6.1 million reinforces the limited-scale assessment, while a cash-burn ratio approaching 1.9 and a low cash-runway subscore align with the stretched condition. Primary regulatory filings show no dated latest filing, producing a weak cadence score despite no regulatory events during the past six months and no enforcement hits.

The principal upside catalyst sits within the strongest pillar: renewed primary regulatory filing activity could lift cadence from its currently depressed level and provide current evidence on whether revenue growth is converting into improved gross and operating margins. Canada’s supportive jurisdiction score and clean enforcement profile already provide the strongest base in the framework, but they cannot offset stale disclosure, negative EBITDA, or the sizable net loss. More consistent filings would also enable institutional pricing feeds and CIN newsroom coverage to evaluate operating progress with greater confidence, potentially strengthening the market and editorial pillars alongside regulatory. The single most important signal to watch is the next dated primary regulatory filing and its evidence of margin conversion.